This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Rigel Pharmaceuticals, Inc.
Drug Names(s): R348
Description: BioMedTracker has separate drug profiles for the oral and topical formulations of R348. Please also see R348 (Topical).
R348 is an orally available inhibitor of Janus Kinase 3 (JAK3), a cytoplasmic tyrosine kinase with expression limited to T cells, B cells, natural killer (NK) cells, mast cells, and macrophages. JAK3 acts in the signal transduction cascade of numerous growth factors used in lymphocyte activation and plays a role in lymphocyte differentiation and proliferation.
R348 (Oral) News
Additional information available to subscribers only: